Medicare for All? Benefits of Part D Model Come Into Sharper Focus for Pharma
This article was originally published in RPM Report
Executive Summary
Medicare’s drug spending grew more than 7% in 2012, according to the latest government statistics. If only the rest of the market worked like Part D.
You may also be interested in...
CMS Proposes Part D Protected Drug Criteria, Drops Antidepressants And Immunosuppressants
A proposed Medicare rule says under new criteria CMS has developed, antidepressants and immunosuppressants will no longer be protected classes in plan formularies, but antineoplastics, antiretrovirals and anticonvulsants will remain. Antipsychotics will also be protected through 2015 as CMS continues to evaluate the class.
Drug Spending Expected To Rise By $200 Bil. In 2022 Compared To Pre-ACA Levels
Implementation of the Affordable Care Act in 2014 will help significantly increase growth for pharma. The increase won’t be as big as it might have been, thanks to the Supreme Court ruling allowing states to opt out of Medicaid expansion, but it should still be a significant acceleration.
A Final Push For US Hepatitis C Eradication Plan In 2024
The Biden Administration is hoping that it can attach funding for a national hepatitis C ‘subscription’ program into the delayed fiscal 2024 appropriations bills.